(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(PRESS RELEASE) ENSCHEDE, Netherlands, 28-Feb-2022 — /EuropaWire/ — University of Twente, a Enschede, NL based public technical university, has announced that its associate professor Kerensa Broersen has been granted Vici funding from NWO, the Dutch Research Council. Kerensa Broersen, associate … Read the full press release
Posted in Education, Financial, Healthcare, Netherlands, Science, Technology
Tagged autism spectrum disorders, Brain, brain function, brain tumours, brain-related disorders, intestinal bacteria, Kerensa Broersen, multiple sclerosis, neurodegeneration, NWO, Parkinson's disease, schizophrenia, Stem cells, TTW, Veni, Vici funding, Vici grant, Vidi grants, ZonMw
Researchers uncover how a microRNA cluster regulates synapse development and sociability HEIDELBERG, 17-Dec-2018 — /EuropaWire/ — The recent discovery of microRNAs as key regulators of biological processes has fueled an explosion of research activity into their function in health and disease. Researchers … Read the full press release
Rxulti® (brexpiprazole) has been approved for the treatment of schizophrenia in adults. VALBY, 01-Aug-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the European Commission has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia … Read the full press release
Posted in Denmark, Healthcare, Pharma & Biotech
Tagged brexpiprazole, European Commission, H. Lundbeck A/S, Ltd, Lundbeck, Otsuka, Otsuka Pharmaceutical Co., Rxulti, schizophrenia
Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis’ leadership in biomedical research and clinical development with Pear’s expertise in digital therapeutics Novartis continues to embrace emerging … Read the full press release
A rare gene variant discovered by UCL scientists is associated with an increased risk of developing schizophrenia, bipolar disorder and alcoholism, confirms new research. LONDON, 25-7-2014 — /EuropaWire/ — People with the variant are around 2 to 3 times more likely to … Read the full press release
Posted in Education, Healthcare, Society, United Kingdom
Tagged alcoholism, bipolar disorder, Dr Andrew McQuillin, Professor David Curtis, rare gene, schizophrenia, UCL scientists
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
